Classifying Adverse Events From Clinical Trials



Similar documents
Principal Investigator and Sub Investigator Responsibilities

Data Safety Monitoring and the IRB. Bertha delanda IRB Training Specialist Research Compliance Office February 2011

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Medical Dictionary for Regulatory Activities (MedDRA) Update

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management

Data Management in Clinical Trials

Clinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

Good Clinical Practice 101: An Introduction

Department of Health and Human Services. Final Guidance Document

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Use of Electronic Health Records in Clinical Research: Core Research Data Element Exchange Detailed Use Case April 23 rd, 2009

How to search the EU Clinical Trials Register

CLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES

12.0 Investigator Responsibilities

Guidance for Clinical Investigators, Sponsors, and IRBs

Janus Clinical Trials Repository (CTR) An Update

2. For all clinical trials, the coverage analysis will also be audited to ensure compliance with the Medicare National Coverage Determination.

Orientation Manual for Clinical Research Coordinators

A Web-Based Data Management System for Small And Medium Clinical Trials

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

Training Guide February, 2015

Classroom Activity: Research Jeopardy!

Clinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group

Using Open Source software and Open data to support Clinical Trial Protocol design

ROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices

Ethical Principles in Clinical Research. Christine Grady Department of Bioethics NIH Clinical Center

Pilot. Pathway into the Future for. Delivery. April 2010 Bron W. Kisler, CDISC Senior Director

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

Jeri & Noboru Oishi Symposium

Risk based monitoring using integrated clinical development platform

Yale Cancer Center Data and Safety Monitoring Committee Charter

Records and Clinical Trials

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

Clinical Investigator Training Course

Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)

Development of Case Report Forms

Cancer Clinical Trials: In-Depth Information

Adopting Site Quality Management to Optimize Risk-Based Monitoring

Compliance Programs in Academic Medical Centers. Georgetown University

UT Health Science Center at San Antonio Research/Grant Records

POLICY. Title: NIAID POLICY ON DATA AND SAFETY MONITORING BOARD (DSMB) OPERATIONS

Objectives. Monitoring & Auditing of Clinical Trials. Overview. Pre-study Qualification Visit. Industry-sponsored Trials

Monitoring & Auditing of Clinical Trials. Sponsored by Center for Cancer Research National Cancer Institute

Pediatric Trials Network. Danny Benjamin MD PhD Professor of Pediatrics Duke University

This policy applies to research administrators, investigators, research staff, Human Investigation Committee (HIC) members and HIC staff.

2014 Metrics on Human Research Protection Program Performance

Guidance on IRB Continuing Review of Research

Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations

11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS

Clinical Trials: Questions and Answers

Friday, May 2. Clinical Trials: Is Your Staff Competent? Session 10:15 11:45 am Ballroom C

Research Coordinator - PI s who have research coordinators or secretarial support can designate individuals to manage their IRB protocols in Mentor.

The Development of the Clinical Trial Ontology to standardize dissemination of clinical trial data. Ravi Shankar

Managing Data in Clinical Research. Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group

Achilles a platform for exploring and visualizing clinical data summary statistics

Use of MedDRA in CTCAE and in the Biopharmaceutical Industry

National Patient Information Reporting System: National Data Warehouse

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA Phone:

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

The Importance of Following the PROTOCOL in Clinical Trials

Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies

Introduction. Editions

Clinical Investigator Inspections and FDA-483 Observations

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

SAS CLINICAL TRAINING

DAIDS Bethesda, MD USA POLICY

National Cancer Institute

Policy on Human Subject Protection Training, Certification and Recertification at AUB

Medical College of Georgia SOP NUMBER: 03 INVESTIGATIONAL DRUG HANDLING Version Number: 1.0, 1.1 Effective Date: 09/12/06, 08/02/10, 3/2/11

INVESTIGATOR HANDBOOK

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Regulatory Binder Instructions 25 April 2016

Roles & Responsibilities of the Sponsor

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

Guidance for IRBs, Clinical Investigators, and Sponsors

The Role of the Clinical Trials Nurse. Objectives. CTN: Protocol Development

The Importance of Good Clinical Data Management and Statistical Programming Practices to Reproducible Research

Adverse Events: Documenting, Recording, and Reporting

Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees

What is Covered under the Privacy Rule? Protected Health Information (PHI)

New Participant Digital Certificate Enrollment Procedure

Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools

INSTITUTIONAL REVIEW BOARD

Pre-Questions. Mastering Clinical Research July 29, 2015

Clinical Data Warehouse Functionality Peter Villiers, SAS Institute Inc., Cary, NC

STANDARD OPERATING POLICY AND PROCEDURE

Clinical Trials: What You Need to Know

Identity Management Framework (IM) Cell

Core Training Outline

Training/Internship Brochure Advanced Clinical SAS Programming Full Time 6 months Program

Research on Research: Learning about Phase 1 Trials

IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others

Clinical Trials: What You Need to Know

A Guide to Clinical Trials

First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases

Human Subjects Research (HSR) Series

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide

Needs, Providing Solutions

Transcription:

Classifying Adverse Events From Clinical Trials Bernard LaSalle, Richard Bradshaw University of Utah, Biomedical Informatics, Salt Lake City, UT USA bernie.lasalle@hsc.utah.edu Abstract The use of adverse event data from investigator- initiated clinical trials, outside of the study event itself, has not been practical because of the absence of uniform data collection. The release of CTCAE 3.0 provided a controlled vocabulary for several components of adverse event data, but was difficult to use in a research setting. We have created a web- based application that combines data from clinical trials and the CTCAE classification information into a queryable database. Introduction The pharmaceutical and device research community has been actively involved in collecting, classifying and reporting adverse events (AEs) since the advent of efforts to improve human subject protection. 1,2 Within this domain there has been acceptance of terminology standards for AEs. However, investigator initiated clinical research makes up the majority of clinical research conducted within the United States 3 and within this domain use of standard terminology and classification is not a common practice. Initial and follow- up reporting of AEs during clinical trials is primarily driven by the regulatory process, which is determined by the requirements of the sponsor, the Food and Drug Administration 4 (FDA) and the Office of Human Research Protection 5 (OHRP). The data collected are used to determine if the AE is serious, if the AE affects the enrollment status of the study participant, and whether the AE is related to the study drug, device or procedure. Once this process is complete, formal classification of the adverse event is required for reports to data and safety monitoring committees and as part of the statistical analysis plan. We have created a straightforward, browser- based application to provide domain experts enough information to classify AEs using the National Cancer Institute Common Terminology Criteria for Adverse Events 6 (CTCAE), which is an initial step in the process of designing an ontology for clinical research AEs. Background Investigator- initiated clinical research in the United States that involves human participants routinely includes processes for identifying AEs and collecting data about the event. Frequently the person(s) collecting these data are clinical coordinators or study nurses and not the principal investigator. When AEs are considered to be serious, a mandatory reporting process is usually started. This process notifies various regulatory entities (IRB, DSMB, sponsor, FDA) 7,8,9 with a

minimum data set of information that fulfills the short- term requirements for reporting, but does not provide enough metadata about the event to be useful outside the context of the initial report. AEs that are determined to be non- serious may not receive any further evaluation other than their frequency. Classifying AEs in a standardized way (system organ class, term, definition, grade and severity) requires someone with domain knowledge of the clinical presentation, the study protocol and the classification standard. Correlating and evaluating all of these data is time consuming, requiring simultaneous review of multiple data sources. Objective Our objective was to create a web- based application that could import AE data from a clinical or device study and display that data, related study data and a search window of CTCAE data within a single browser page. This display allows a domain expert to quickly evaluate the AE data, determine the correct CTCAE classification and then, with a few mouse clicks, link these data and store them in a new AE classification table which is associated with the study meta data. Methods Since the application is database driven, we needed a data model that could import research data with a minimum of extraction- transpose- load (ETL) effort. Only meta data about the study and a subset of the AE data are imported into two tables (Figure 1). This is currently a manual process using a formatted text export file or a direct SQL query of the study database. The published NCI CTCAE data are loaded into multiple tables by a similar process; however, since this is a known structure, the process is straightforward and required only when CTCAE data are updated. The CTCAE data are loaded into three tables in a relational database, PostgreSQL, 10 to enable faster searching by the person evaluating the AEs (Figure 2). The application interface allows the user to select a study that filters the display of AE data. As each AE is displayed, the user can select a System Organ Class (SOC), filtering the number of AE terms displayed, or an AE term directly. Once the Preferred Term has been selected, the corresponding Grades are displayed. Once the Grade has been chosen, all of the data from both data sources are ready to be inserted into the Evaluated AE table (Figure 3).

Figure 1 depicts the loading of clinical study data to be classified into the application database tables. Only data relevant to classifying the AE are loaded. Figure 2 shows the reorganization of CTCAE data into relational tables. Each System Organ Class contains the AE preferred terms within the class and each term has several possible Grades. Results The application allows users to view AEs in a browser interface within a single device screen. Users have the ability to view only AEs that require classification, filtered by study. A search engine allows users to reduce the focus of data being displayed by selecting either the SOC or the term relevant to the AE being classified. Once the user has determined the correct classification, she then selects the correct grade. The associated classification data and AE data from the study are automatically populated into a data table. Previously classified AEs can be reviewed and edited within the same interface. Meta data about the study are assigned a unique identification number that is associated with each classified AE. This allows comparison of AEs within a single trial or across trials when appropriate.

Figure 3 shows the process flow 1) Selecting a study and a single AE from the subset of AEs filtered by the study ID; 2) Selecting the SOC and a single preferred term filtered by the SOC; 3) Selecting a grade from the grades associated with the preferred term. The data from these three steps are merged and stored. Conclusion Individual research sites and data centers will use a variety of data models and data sources when collecting clinical research data. We have created an application that simplifies importing AE data though the use of mapping tables during the ETL process. By using an existing classification standard (CTCAE) and a standard results table, we can standardize the AEs from multiple trials once they are classified. The resulting data can now form the basis for discussions about whether CTCAE is the most appropriate classification system, whether the meta data collected are sufficient to compare AEs across trials, and how this could contribute to the creation of an ontology for AEs. The classifying and reuse of adverse event data can be a significant contribution to patient safety, and is critical to orphan disease clinical research, particularly within pediatric populations. Standardized vocabularies and concepts of AEs may allow

investigators to reuse safety data from previous clinical research, which would significantly reduce the cost and length of clinical research trials. References 1. The National Research Act, United States Congress, 1974. 2. The Belmont Report, Ethical Principles and Guidelines for the protection of human subjects of research, Department of Health, Education and Welfare, 1979 3. The Investigator- sponsored IND in clinical trials, Haakenson C, Fye CL, Sather MR, Toussaint DJ, Control Clin Trials. 1987 Jun;8(2):101-9. 4. The Food and Drug Administration, Department of Health and Human Services, United States of America, 1930. 5. Office of Human Research Protection, Department of Health and Human Services, United States of America, 1966. 6. Common Terminology Criteria for Adverse Events, National Cancer Institute, National Institutes of Health, United States of America, August 9, 2006. 7. Institutional Review Board, National Research Act of 1974, USA, are governed by Title 45 CFR (Code of Federal Regulations) Part 46, National Institutes of Health, Department of Health and Human Services, United States of America. 8. Data and Safety Monitoring Board (DSMB), NIH Policy For Data and Safety Monitoring, National Institutes of Health, United States of America, June 10, 1998. 9. Sponsor, The entity responsible for registering the study is the responsible party., as defined in 21 CFR (Code of Federal Regulations), Part 21 CFR 50.3, National Institutes of Health, Department of Health and Human Services, United States of America. 10. PostgreSQL 9.0.0 Documentation. PostgreSQL Global Development Group. Retrieved 2010-09- 20.